Form 4 for DGX Quest Diagnostics
Accepted 2024-09-03 00:00:00 ET · period of report 2024-08-29 · accession 0001022079-24-000176 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-09-03 | 2024-08-29 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale+OE | $154.97 | -32.6K | 38.5K | -46% | -$5.04M |
| D | 2024-09-03 | 2024-08-29 | DGX | PREVOZNIK MICHAEL E | SVP, GC | M - OptEx | $95.80 | +32.6K | 71.0K | +85% | +$3.12M |
| D | 2024-09-03 | 2024-08-29 | DGX | PREVOZNIK MICHAEL E | SVP, GC | M - OptEx | $95.80 | -32.6K | 0 | -100% | -$3.12M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-29 | S | D | 32,551 | $154.97 | 38,478 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $154.890 to $155.455. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2024-08-29 | M | A | 32,551 | $95.80 | 71,029 | D | — | — | |
| 3 | Derivative | Non-Qualifed Stock Option (right to buy) | 2024-08-29 | M | D | 32,551 | $95.80 | 0 | D | $95.80 · — to 2027-02-21 | 32,551 Common Stock | (F3) The options vested in three annual installments beginning with the first on February 21, 2018, the second on February 21, 2019 and the final on February 21, 2020. |